These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21504907)

  • 1. K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.
    Ahmad I; Singh LB; Foth M; Morris CA; Taketo MM; Wu XR; Leung HY; Sansom OJ; Iwata T
    Dis Model Mech; 2011 Jul; 4(4):548-55. PubMed ID: 21504907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
    Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
    Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.
    Duperret EK; Oh SJ; McNeal A; Prouty SM; Ridky TW
    Cell Cycle; 2014; 13(10):1551-9. PubMed ID: 24626198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.
    Ahmad I; Patel R; Liu Y; Singh LB; Taketo MM; Wu XR; Leung HY; Sansom OJ
    Cell Death Dis; 2011 Mar; 2(3):e124. PubMed ID: 21368895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
    Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
    Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
    Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
    Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
    Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
    Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
    Chandrani P; Prabhash K; Prasad R; Sethunath V; Ranjan M; Iyer P; Aich J; Dhamne H; Iyer DN; Upadhyay P; Mohanty B; Chandna P; Kumar R; Joshi A; Noronha V; Patil V; Ramaswamy A; Karpe A; Thorat R; Chaudhari P; Ingle A; Choughule A; Dutt A
    Ann Oncol; 2017 Mar; 28(3):597-603. PubMed ID: 27998968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 mutations in prostate cancer: association with low-grade tumors.
    Hernández S; de Muga S; Agell L; Juanpere N; Esgueva R; Lorente JA; Mojal S; Serrano S; Lloreta J
    Mod Pathol; 2009 Jun; 22(6):848-56. PubMed ID: 19377444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 mutations in benign skin tumors.
    Hafner C; Vogt T; Hartmann A
    Cell Cycle; 2006 Dec; 5(23):2723-8. PubMed ID: 17172848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
    di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
    Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
    Yee CH; Zheng Z; Shuman L; Yamashita H; Warrick JI; Wu XR; Raman JD; DeGraff DJ
    Sci Rep; 2019 Jan; 9(1):270. PubMed ID: 30670749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.